


# PRODUCT INFORMATION



## ARN-509

Item No. 17132

**CAS Registry No.:** 956104-40-8  
**Formal Name:** 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide  
**Synonym:** JNJ-56021927  
**MF:** C<sub>21</sub>H<sub>15</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub>S  
**FW:** 477.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 246 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

ARN-509 is supplied as a crystalline solid. A stock solution may be made by dissolving the ARN-509 in the solvent of choice, which should be purged with an inert gas. ARN-509 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ARN-509 in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

ARN-509 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ARN-509 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ARN-509 has a solubility of approximately 0.1 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

ARN-509 is an antagonist of the androgen receptor (IC<sub>50</sub> = 16 nM).<sup>1</sup> It binds the receptor but does not cause nuclear localization or DNA binding.<sup>1</sup> ARN-509 is orally bioavailable and, at 30 mg/kg/d, suppresses tumor growth in a mouse model of castration-resistant prostate cancer.<sup>1</sup> This compound can be used to study androgen signaling *in vitro* and *in vivo* and has potential applications in certain types of cancer.<sup>2</sup>

### References

1. Clegg, N.J., Wongvipat, J., Joseph, D.J., *et al.* ARN-509: A novel antiandrogen for prostate cancer treatment. *Cancer Res.* **72**(6), 1494-1503 (2012).
2. Gupta, E., Guthrie, T., and Tan, W. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). *BMC Urol.* **14**, 55 (2014).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)